We have previously reported lack of expression of a polypeptide designated L3 in infant acute lymphoblastic leukemia (ALL). Expression of L3 occurred predominantly in older children with pre-B ALL. We have recently reported the expression during B cell ontogeny of two other polypeptides, designated L2 and L4 with a similar Mr as L3, which were identified as phosphorylated and non-phosphorylated forms respectively of the low Mr heat shock protein, hsp27. In this study we have characterized L3 and identified it as another phosphorylated form of hsp27. The two phosphorylated forms appear to be differentially expressed in acute leukemia. L3 levels in infants who expressed hsp27 isoforms L2 and L4 were significantly diminished compared to levels in older children with an equivalent amount of hsp27. We conclude that leukemic cells in infant ALL exhibit a unique pattern of phosphorylation of hsp27 expressed at a pre-B cell stage of differentiation.
subjects in accordance with institutional guidelines. For analysis of the quantitative relationship between L3 expression and expression of L2 and I.,4, we utilized a portion of our leukemia cell two-dimensional gel data base consisting of a group of 13 infants (<12 months) and 79 children (2 to 7 years) with pre-B ALL studied at the time of initial diagnosis. Specific diagnoses were made as previously described (1) . Leukemic cells were obtained by Ficoll-Hypaque gradient centrifugation and constituted 85% or more of the total mononuclear cells. Additional samples included peripheral blood lymphocytes from four normal individuals, four T cell clones derived from a single non-leukemic individual (3), the erythroleukemia cell line K562, and an EBVtransformed B lymphoblastoid cell line derived from a non-leukemic individual with Bloom syndrome.
Cell Culture and 32Pi Labeling: Cell lines and T cell clones were cultured in RPMI 1640 supplemented with 10% fetal bovine serum. Normal peripheral blood lymphocytes or patient lymphoblasts were maintained in culture medium at 37 ° C overnight prior to labeling with 32p i. Cells (5 x 106) were incubated with PO4-free RPMI 1640 for 30 min.
[32p] H3PO4 (Amersham, carrier free) was added at 0.25 mCi/ml for 2 h at 37°C. For heat shock treatment, cells were incubated at 42 ° C for 2 h and returned to 37 ° C overnight to allow newly synthesized protein to accumulate or 32p i labeling was done immediately following heat shock. Identical flasks maintained at 37 ° C served as controls. Cells were washed three times with phosphate buffered saline, pelleted at 3,000 x g and stored as frozen pellets at -80 ° C. Two-dimensional Electrophoresis: 2-D PAGE was done using a carrier ampholyte-based first dimension system as previously described (11) . For the second-dimension separation, an acrylamide gradient of 11.4-14.0 g/dl was used. Protein spots in gels were visualized either with silver-staining (12) or by autoradiography. Autoradiographs were prepared using Kodak X-Omat AR film with intensifying screens at ~80 o C. purification and Peptide Mapping of L2 and L3: Polypeptides were isolated from K562 cells following heat shock treatment or from cells of a 2 year old patient with pre-B ALL. Solubilized proteins were separated by 2-D PAGE (15 x 106 cell equivalents per gel). Phosphorylated polypeptides were located on dried gels by autoradiography and excised. Gel pieces were rehydrated with distilled deionized water, separated from the paper backing, extensively washed with water and lyophilized. Greater than 10 fold excess of TPCK-trypsin (0.5 ml; 1 mg/ml in 0.2 M ammonium bicarbonate, pH 8.2) was added and digestion proceeded overnight at 37°C. Tryptic peptides were eluted with 0.1%, v/v, trifluoroacetic acid (TFA) and applied to a C4 reverse phase column (4.2 x 100 mm, 10g, Vydac) equilibrated with solvent A (0.1%, v/v, TFA in water). Peptides were eluted with a gradient of solvent B (0.075% TFA in acetonitrile) from 0% to 40% B in 40 min, then to 80% B in 20 min and finally to 100% B in 5 min. Fractions (0.5 min) were collected and 32p-peptides detected by liquid scintillation counting. As an internal control for reproducibility of peptide elution times, column eluant was monitored at 214 nm to detect trypsin, its autodigestion products and other uv absorbing components eluted from the in situ gel digests. Identical uv absorbance tracings were observed for these components from all samples analyzed. Retention times for each component varied by less than 0.3 min over the range of elution times within which 32p-peptides were eluted.
Quantification of Polypeptides: Gels were scanned in a 1024 x 1024 pixel format and spot detection and quantitation were performed as previously described (3) . Twenty reference spots were used to adjust the L3, L2 and L4 spot integrated intensities using the mean ratio adjustment method (13) . Gels exhibiting L3, L2 and L4 spots that were readily detectable by visual inspection of the gel yielded an inte~ated intensity greater than 0.40.D. x mm 2. Therefore, this value was chosen as a cutoff for categorizing cases with absence of L3, L2 or IA.
RESULTS
Identification of L3 as a Phosphorylated Polypeptide: Lymphoblasts from pre-B ALL patients which express L3, L2 and L4 were labeled in culture with 32p i for 2 h. Polypeptides were separated by 2D polyacrylamide gel electrophoresis. Gels were silver stained and autoradiograms Cells were untreated or heat shocked for 2 h at 42°C and then labelled with 32p i for 2h at 37oc. Phosphorylated polypeptides were separated by 2D PAGE and quantitated from autoradiographs as described in "Methods". hold of silver-staining. The amount of pp b relative to pp a in K562 cells (Fig. 2C ) and in the B cell line (Fig. 2D ) agrees with the abundance of L3 and L2 respectively on silver stained gels. Pp a and pp b are also unambiguously associated with silver-stained spots identified as L2 and L3 in the B and K562 cell lines (data not shown). In lymphoblasts, radioactivity corresponding to pp c does not correspond to a discrete silver-stained spot (cf., large white arrow Fig. 1A ) due to the close proximity of two large non-phosphorylated polypeptides. K562 cells do not express these polypeptides and a faint spot can be identified at the location ofpp c on the silver-stained gel.
Expression of L3 in response to heat shock: Hsp27 polypeptides L2 and L4 were previously shown to be induced in T cell clones which do not normally express these polypeptides or to increase two to four fold in ALL 16 h after heat shock during which time newly synthesized protein could accumulate (3). Reexamination of those silver-stained gels revealed a small amount 
DISCUSSION
The data presented in this study demonstrates the structural relatedness of L3 to L2 and La.
The findings of increased levels of L3 in response to heat shock and the similarities of the HPLC phosphopeptide chromatographs of L3 and L2 allow us to conclude that L3 is the product of progressive phosphorylation of hsp27.
It is becoming increasingly evident that the proteins associated with cellular heat shock response play an important role in the normal function of a variety of cell types outside of the heat shock response (14) (15) (16) . While specific functions have been determined in non-stressed cells for several of the major heat shock protein families, such as hsp90 (16) , hsp70 (15) and hsp58 (17) , specific functions for members of the hsp27 family have not been established. Synthesis of hsp70 (18, 19) and hsp27 (20, 21) during development suggest that they serve a role in cell differentiation. The results we have obtained lead us to conclude that phosphorylation of hsp27 to form L3, distinguishes between infant ALL and the majority of cases of pre-B ALL in older children. It has been previously shown that a large proportion of infant ALL represent leukemic cells that are arrested at a pre-B stage of differentiation prior to CALLA expression (15, 16) . We have previously demonstrated that expression of hsp27 substantially overlaps with CALLA expression.
Our prior observation that some pre-B ALL cases that expressed CD19 also expressed hsp27 but failed to express CALLA led us to suggest that expression of hsp27 occurs after CD19 and precedes CALLA (3). The identification of L3 as a phosphorylated form of hsp27, delineates an additional subtype of pre-B ALL. Thus, the CD19 positive, hsp27 positive group can be divided into two subtypes, based on the occurrence of L3. The CD 19 positive, hsp27 positive (L2 and L4), L3 negative group predominates in infants and the CD19 positive, hsp27 and L3 positive group predominates in older children, most of whom are also CALLA positive.
The mechanism accounting for differentiation stage-specific difference in phosphorylation status of hsp27 is unknown. Studies of hsp27 phosphorylation in human mammary carcinoma cell lines (5) and other immature cell types (6) (7) (8) 20) have implicated Ca++/phospholipid dependent protein kinase C (PKC). In human leukemia and lymphoma cell lines, total PKC activity was found to be lower in B-cell and cell lines identified as non-T non-B, compared to T-cell lines (22) .
Decreased PKC activity may be responsible for the variability in expression of L2 which we have observed (3), however decreased kinase activity alone may not account for the difference in hsp27 phosphorylation status between L2 and L3. Several possibilities exist including involvement of a) a protein kinase other than PKC similar to that reported for tumor necrosis factor-mediated phosphorylation of this heat shock protein (23), b) differential expression or activation of PKC subtypes, or their down-regulation due to chronic activation, c) presence of a protein kinase inhibitor and d) differential stability of L3 and L2 due to specific phosphatases or proteases. The extent to which differential phosphorylation of hsp27 in leukemic cells contributes to treatment outcome remains to be determined. Preliminary analysis of relapse rates for patients lacking L3 is about twice as high as that for patients expressing L3, even after excluding the infant group (Hanash, unpublished) . Differential phosphorylation of hsp27, and possibly other proteins, suggests key differences in regulation of metabolic activity between these patient groups which may be crucial to treatment outcome.
